Developer docs
API playgroundTry for free, no card

Search company profiles

BioCytex

Full company profile

uuid002gmi7

Namestring
BioCytex
Legal namestring
BIOCYTEX S.A.R.L
Websiteurl
biocytex.fr
Company typeenum
Private
Founded yearint
1992
Descriptiontext

BioCytex S.A.R.L is a French specialty biotechnology company headquartered in Marseille, France, operating as a wholly-owned subsidiary of Diagnostica Stago S.A.S, a global hemostasis diagnostics conglomerate. The company specializes in flow cytometry-based diagnostic products, monoclonal antibody production, and custom development services for the pharmaceutical and clinical diagnostics industries, with particular focus on hemostasis, thrombosis, and microvesicle analysis. BioCytex was founded in 1992 and operates with 11-50 employees, functioning as a focused R&D and specialty product unit within the larger Stago Group portfolio.

The company's product portfolio centers on ready-to-use flow cytometry kits for antigen quantification in small sample volumes with heterogeneous cell populations, calibration tools (Megamix beads, MP-Count Beads) for standardized microvesicle analysis, and the CY-QUANT MV-TF Activity chromogenic assay for measuring tissue factor activity on microvesicles with a detection limit of 3+/-1 fM, compliant with ISTH 2019 international recommendations. BioCytex also offers custom development services including monoclonal antibody production (with over 10 years of experience and 2-3 month delivery cycles), hybridoma development, antibody engineering, immunoglobulin fragmentation and conjugation, and immunomonitoring and biosimilar antibody validation services for international pharmaceutical companies engaged in pre-clinical and clinical drug development.

The business model combines one-time sales of diagnostic kits and reagents with professional services revenue from custom development engagements, both delivered via a quote-based B2B enterprise model. Distribution leverages the Stago Group's global network spanning 15+ countries. BioCytex maintains scientific partnerships with ISTH, GEHT, and AFC, and in December 2025 launched the NVDIAG LabCom joint laboratory with LISM (CNRS/Aix-Marseille Université), ANR, and Région Sud to develop nano-antibody diagnostics for multiple myeloma and acute leukemias—signaling expansion into hematological oncology. The company occupies a defensible niche as a specialty flow cytometry and microvesicle analysis brand within Stago Group's hemostasis-focused portfolio.

Short descriptiontext

BioCytex is a French specialty biotechnology subsidiary of Diagnostica Stago that develops flow cytometry kits, monoclonal antibodies, and custom diagnostic services for hemostasis, microvesicle analysis, and pharmaceutical drug development clients worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarseille, France
HQ citystring
Marseille
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
flow cytometry kits, monoclonal antibody production, microvesicle analysis, hemostasis diagnostics, tissue factor testing
Industry4 codes
PRIMARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Hemostasis Diagnostics Reagents
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Diagnostic products and kits
TypeOne Time License
Description

Sale of ready-to-use flow cytometry kits and microvesicle analysis products including CY-QUANT MV-TF Activity, MP-Count Beads, and Megamix calibration beads

biocytex.fr
2Custom development services
TypeProfessional Services
Description

Customized services for international pharmaceutical companies including immunomonitoring development and biosimilar antibody validation for pre-clinical and clinical drug development

biocytex.fr
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1CY-QUANT MV-TF Activity
Description

A chromogenic test measuring tissue factor (TF) activity in microvesicles (MV), compliant with international ISTH recommendations

biocytex.fr
Core offering1 text field

BioCytex develops and sells ready-to-use flow cytometry kits and chromogenic assays for antigen quantification, microvesicle analysis, and tissue factor (TF) activity measurement, alongside custom development services including in vitro monoclonal antibody production and immunomonitoring/biosimilar antibody validation for pharmaceutical clients. Its portfolio includes the CY-QUANT MV-TF Activity test, Megamix and MP-Count calibration beads, and proprietary kits for hemostasis and cell-based diagnostics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • CY-QUANT MV-TF Activity achieves very high sensitivity with a limit of detection of 3+/-1 fM
Product overview1 text field

BioCytex offers a portfolio of diagnostic products and services for hemostasis and microvesicle analysis. Core products include the CY-QUANT MV-TF Activity chromogenic test for tissue factor activity measurement, flow cytometry kits, and calibration tools (Megamix, MP-Count Beads). The company also provides custom development services including monoclonal antibody production and immunomonitoring validation for pharmaceutical clients. Products are part of the Stago Group diagnostic ecosystem.

Product and service8 records
1CY-QUANT MV-TF Activity
CategoryDiagnostic Reagents
Description

A chromogenic test that measures tissue factor (TF) activity on microvesicles (MV) with high sensitivity and specificity, compliant with international ISTH recommendations, intended for clinical diagnostics and research laboratories working in hemostasis.

2Flow Cytometry Kits
CategoryDiagnostic Reagents
Description

A range of ready-to-use flow cytometry kits for antigen quantification in small sample volumes containing few cells and heterogeneous populations, enabling analysis of cell size, content, and fluorescence intensity.

3CRP-A
CategoryDiagnostic Reagents
Description

Catalog product listed in the BioCytex product catalog for diagnostic or research use.

4Megamix Calibration Beads
CategoryCalibration Tools
Description

Calibration beads used as a sizing tool for flow cytometry analysis of microvesicles, optimized for each type of cytometer to enable standardized microvesicle analysis.

5MP-Count Beads
CategoryCalibration Tools
Description

Bead suspension designed for absolute counting of microvesicles in flow cytometry applications.

6STA Procoag PPL
CategoryDiagnostic Reagents
Description

Functional test for measuring procoagulant phospholipid activity of microvesicles.

7Monoclonal Antibody Production Services
CategoryCustom Services
Description

In vitro production of mouse monoclonal antibodies in 2-3 months with over 10 years of experience; services include hybridoma development, antibody engineering, and immunoglobulin fragmentation and conjugation.

8Custom Development Services
CategoryCustom Services
Description

Customized immunomonitoring development and biosimilar antibody validation services for international pharmaceutical companies engaged in pre-clinical and clinical drug development and biomarker research.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1LISM (Laboratoire d'Ingénierie des Système Macromoléculaires - CNRS/Aix-Marseille Université)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-12-16
Description

Strategic alliance forming NVDIAG LabCom (Laboratoire Commun) focused on developing innovative nano-antibodies for improved diagnostic tests for multiple myeloma and acute leukemias. The partnership leverages synergy between BioCytex's diagnostic expertise and LISM's macromolecular engineering research capabilities.

biocytex.fr
2ANR (Agence nationale de la recherche)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Funding agency partner in the NVDIAG LabCom initiative, supporting the joint research program for developing next-generation diagnostic tools using innovative biological mechanisms.

biocytex.fr
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Regional government partner co-funding the NVDIAG LabCom laboratory together with ANR, supporting regional innovation in medical diagnostics.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

BioCytex is a subsidiary (Société à Responsabilité Limitée) of Diagnostica Stago S.A.S, headquartered in Asnières-sur-Seine, France. Stago is a major player in hemostasis diagnostics with global presence.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Specialized nano-flow cytometry platform focused on nanoparticle and microvesicle analysis. Closest emerging competitor to BioCytex's CY-QUANT MV-TF Activity and Megamix/MP-Count Beads microvesicle workflow, targeting the same research and clinical lab segment.

2Beckman Coulter
TypeDirect peer
Description

Major flow cytometry instruments and reagent provider with a comparable antibody/reagent portfolio. BioCytex has explicitly validated interoperability of its anti-Kappa/Lambda assays with Beckman Coulter platforms, making them direct competitors in flow cytometry reagents for clinical diagnostics.

TypeDirect peer
Description

Global life science tools company with significant flow cytometry reagents, antibody kits, and clinical diagnostics offerings. Directly competes with BioCytex in ready-to-use flow cytometry kits and immunology assay reagents for research and clinical labs.

TypeBroad incumbent
Description

Global in vitro diagnostics leader with a strong hemostasis and coagulation testing franchise that overlaps BioCytex's hemostasis/thrombosis focus area. Much broader portfolio but directly competes in clinical hemostasis diagnostics where BioCytex's microvesicle and tissue factor assays are positioned.

TypeBroad incumbent
Description

BioCytex's parent company and global leader in hemostasis diagnostics. Comparable in hemostasis product portfolio, customer base (clinical labs and hospitals), and channel strategy; BioCytex operates as a specialized brand within the Stago ecosystem.

TypeDirect peer
Description

Flow cytometry, cell analysis, and antibody reagent specialist with strong pharma services franchise. Comparable to BioCytex in monoclonal antibody offerings, flow cytometry kits, and custom services for clinical research.

TypeDirect peer
Description

Leading flow cytometry instruments, antibodies, and reagent kits provider serving pharma, biotech, and clinical research customers. Comparable to BioCytex in offering flow cytometry-based assays and antibody-based diagnostic/research tools.

TypeDirect peer
Description

Specialized antibody and assay kit developer for research and clinical diagnostics. Comparable to BioCytex in producing high-quality monoclonal antibodies and assay reagents targeting specific biomarkers for the research and pharma services market.

TypeBroad incumbent
Description

Diversified life sciences tools giant offering flow cytometry (via Life Technologies), antibodies, reagents, and pharma services. Overlaps with BioCytex's flow cytometry kits, antibody production, and custom services for pharma R&D at much greater scale.

TypeDirect peer
Description

Global antibody reagent supplier serving research and diagnostic markets with a deep catalog of monoclonal and polyclonal antibodies. Comparable to BioCytex's custom antibody production and reagent development business for research and clinical applications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioCytex

Hemostasis Diagnostics Reagentsbiocytex.fr

BioCytex is a French specialty biotechnology subsidiary of Diagnostica Stago that develops flow cytometry kits, monoclonal antibodies, and custom diagnostic services for hemostasis, microvesicle analysis, and pharmaceutical drug development clients worldwide.

What BioCytex does

BioCytex S.A.R.L is a French specialty biotechnology company headquartered in Marseille, France, operating as a wholly-owned subsidiary of Diagnostica Stago S.A.S, a global hemostasis diagnostics conglomerate. The company specializes in flow cytometry-based diagnostic products, monoclonal antibody production, and custom development services for the pharmaceutical and clinical diagnostics industries, with particular focus on hemostasis, thrombosis, and microvesicle analysis. BioCytex was founded in 1992 and operates with 11-50 employees, functioning as a focused R&D and specialty product unit within the larger Stago Group portfolio.

The company's product portfolio centers on ready-to-use flow cytometry kits for antigen quantification in small sample volumes with heterogeneous cell populations, calibration tools (Megamix beads, MP-Count Beads) for standardized microvesicle analysis, and the CY-QUANT MV-TF Activity chromogenic assay for measuring tissue factor activity on microvesicles with a detection limit of 3+/-1 fM, compliant with ISTH 2019 international recommendations. BioCytex also offers custom development services including monoclonal antibody production (with over 10 years of experience and 2-3 month delivery cycles), hybridoma development, antibody engineering, immunoglobulin fragmentation and conjugation, and immunomonitoring and biosimilar antibody validation services for international pharmaceutical companies engaged in pre-clinical and clinical drug development.

The business model combines one-time sales of diagnostic kits and reagents with professional services revenue from custom development engagements, both delivered via a quote-based B2B enterprise model. Distribution leverages the Stago Group's global network spanning 15+ countries. BioCytex maintains scientific partnerships with ISTH, GEHT, and AFC, and in December 2025 launched the NVDIAG LabCom joint laboratory with LISM (CNRS/Aix-Marseille Université), ANR, and Région Sud to develop nano-antibody diagnostics for multiple myeloma and acute leukemias—signaling expansion into hematological oncology. The company occupies a defensible niche as a specialty flow cytometry and microvesicle analysis brand within Stago Group's hemostasis-focused portfolio.

BioCytex firmographics

Firmographics
Name
BioCytex
Legal name
BIOCYTEX S.A.R.L
Website
https://biocytex.fr
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
11–50 employees
Short description
BioCytex is a French specialty biotechnology subsidiary of Diagnostica Stago that develops flow cytometry kits, monoclonal antibodies, and custom diagnostic services for hemostasis, microvesicle analysis, and pharmaceutical drug development clients worldwide.
Ownership category
akta.pro rank

BioCytex industry classification

Industry
Product category
Hemostasis Diagnostics Reagents
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAHAAAF
Flow Cytometry & Cellular Analysis Diagnostics
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Flow cytometry kits
  • Monoclonal antibody production
  • Microvesicle analysis
  • Hemostasis diagnostics
  • Tissue factor testing

Where BioCytex is headquartered

Location

Headquarters

HQ city
Marseille
HQ country
France
HQ region
Europe

Offices2 records

Markets served

BioCytex business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. Diagnostic products and kits: Sale of ready-to-use flow cytometry kits and microvesicle analysis products including CY-QUANT MV-TF Activity, MP-Count Beads, and Megamix calibration beads
  2. Custom development services: Customized services for international pharmaceutical companies including immunomonitoring development and biosimilar antibody validation for pre-clinical and clinical drug development

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

BioCytex product offering

Product offering

Core offering

BioCytex develops and sells ready-to-use flow cytometry kits and chromogenic assays for antigen quantification, microvesicle analysis, and tissue factor (TF) activity measurement, alongside custom development services including in vitro monoclonal antibody production and immunomonitoring/biosimilar antibody validation for pharmaceutical clients. Its portfolio includes the CY-QUANT MV-TF Activity test, Megamix and MP-Count calibration beads, and proprietary kits for hemostasis and cell-based diagnostics.

Product overview

BioCytex offers a portfolio of diagnostic products and services for hemostasis and microvesicle analysis. Core products include the CY-QUANT MV-TF Activity chromogenic test for tissue factor activity measurement, flow cytometry kits, and calibration tools (Megamix, MP-Count Beads). The company also provides custom development services including monoclonal antibody production and immunomonitoring validation for pharmaceutical clients. Products are part of the Stago Group diagnostic ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

  • CY-QUANT MV-TF Activity: A chromogenic test measuring tissue factor (TF) activity in microvesicles (MV), compliant with international ISTH recommendations

Products and services

  • CY-QUANT MV-TF Activity A chromogenic test that measures tissue factor (TF) activity on microvesicles (MV) with high sensitivity and specificity, compliant with international ISTH recommendations, intended for clinical diagnostics and research laboratories working in hemostasis.
  • Flow Cytometry Kits A range of ready-to-use flow cytometry kits for antigen quantification in small sample volumes containing few cells and heterogeneous populations, enabling analysis of cell size, content, and fluorescence intensity.
  • CRP-A Catalog product listed in the BioCytex product catalog for diagnostic or research use.
  • Megamix Calibration Beads Calibration beads used as a sizing tool for flow cytometry analysis of microvesicles, optimized for each type of cytometer to enable standardized microvesicle analysis.
  • MP-Count Beads Bead suspension designed for absolute counting of microvesicles in flow cytometry applications.
  • STA Procoag PPL Functional test for measuring procoagulant phospholipid activity of microvesicles.
  • Monoclonal Antibody Production Services In vitro production of mouse monoclonal antibodies in 2-3 months with over 10 years of experience; services include hybridoma development, antibody engineering, and immunoglobulin fragmentation and conjugation.
  • Custom Development Services Customized immunomonitoring development and biosimilar antibody validation services for international pharmaceutical companies engaged in pre-clinical and clinical drug development and biomarker research.

Quantifiable outcome

  • CY-QUANT MV-TF Activity achieves very high sensitivity with a limit of detection of 3+/-1 fM

Companies that use BioCytex

Customer profile

Segments2 records

Ideal customer profiles2 records

BioCytex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BioCytex partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • LISM (Laboratoire d'Ingénierie des Système Macromoléculaires - CNRS/Aix-Marseille Université)coreStrategic or Co-development Partner · 16 December 2025Strategic alliance forming NVDIAG LabCom (Laboratoire Commun) focused on developing innovative nano-antibodies for improved diagnostic tests for multiple myeloma and acute leukemias. The partnership leverages synergy between BioCytex's diagnostic expertise and LISM's macromolecular engineering research capabilities.
  • ANR (Agence nationale de la recherche)coreStrategic or Co-development PartnerFunding agency partner in the NVDIAG LabCom initiative, supporting the joint research program for developing next-generation diagnostic tools using innovative biological mechanisms.
  • Région Sud - Provence-Alpes-Côte d'AzurcoreStrategic or Co-development PartnerRegional government partner co-funding the NVDIAG LabCom laboratory together with ANR, supporting regional innovation in medical diagnostics.
  • Diagnostica Stago S.A.S (Parent Company)coreStrategic or Co-development PartnerBioCytex is a subsidiary (Société à Responsabilité Limitée) of Diagnostica Stago S.A.S, headquartered in Asnières-sur-Seine, France. Stago is a major player in hemostasis diagnostics with global presence.

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

BioCytex competitors and assessment

Company assessment

Emerging players

  • NanoFCM: Specialized nano-flow cytometry platform focused on nanoparticle and microvesicle analysis. Closest emerging competitor to BioCytex's CY-QUANT MV-TF Activity and Megamix/MP-Count Beads microvesicle workflow, targeting the same research and clinical lab segment.

Direct peers

  • Beckman Coulter: Major flow cytometry instruments and reagent provider with a comparable antibody/reagent portfolio. BioCytex has explicitly validated interoperability of its anti-Kappa/Lambda assays with Beckman Coulter platforms, making them direct competitors in flow cytometry reagents for clinical diagnostics.
  • Bio-Rad Laboratories: Global life science tools company with significant flow cytometry reagents, antibody kits, and clinical diagnostics offerings. Directly competes with BioCytex in ready-to-use flow cytometry kits and immunology assay reagents for research and clinical labs.
  • Miltenyi Biotec: Flow cytometry, cell analysis, and antibody reagent specialist with strong pharma services franchise. Comparable to BioCytex in monoclonal antibody offerings, flow cytometry kits, and custom services for clinical research.
  • BD Biosciences: Leading flow cytometry instruments, antibodies, and reagent kits provider serving pharma, biotech, and clinical research customers. Comparable to BioCytex in offering flow cytometry-based assays and antibody-based diagnostic/research tools.
  • Cell Signaling Technology: Specialized antibody and assay kit developer for research and clinical diagnostics. Comparable to BioCytex in producing high-quality monoclonal antibodies and assay reagents targeting specific biomarkers for the research and pharma services market.
  • Abcam: Global antibody reagent supplier serving research and diagnostic markets with a deep catalog of monoclonal and polyclonal antibodies. Comparable to BioCytex's custom antibody production and reagent development business for research and clinical applications.

Broad incumbents

  • Sysmex: Global in vitro diagnostics leader with a strong hemostasis and coagulation testing franchise that overlaps BioCytex's hemostasis/thrombosis focus area. Much broader portfolio but directly competes in clinical hemostasis diagnostics where BioCytex's microvesicle and tissue factor assays are positioned.
  • Diagnostica Stago: BioCytex's parent company and global leader in hemostasis diagnostics. Comparable in hemostasis product portfolio, customer base (clinical labs and hospitals), and channel strategy; BioCytex operates as a specialized brand within the Stago ecosystem.
  • Thermo Fisher Scientific: Diversified life sciences tools giant offering flow cytometry (via Life Technologies), antibodies, reagents, and pharma services. Overlaps with BioCytex's flow cytometry kits, antibody production, and custom services for pharma R&D at much greater scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

BioCytex social profiles

Digital presence

BioCytex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioCytex leadership team

Management profile

Number of profiles

Profiles1 record

BioCytex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioCytex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioCytex

What does BioCytex do?

BioCytex develops and sells ready-to-use flow cytometry kits and chromogenic assays for antigen quantification, microvesicle analysis, and tissue factor (TF) activity measurement, alongside custom development services including in vitro monoclonal antibody production and immunomonitoring/biosimilar antibody validation for pharmaceutical clients. Its portfolio includes the CY-QUANT MV-TF Activity test, Megamix and MP-Count calibration beads, and proprietary kits for hemostasis and cell-based diagnostics.

Is BioCytex a public or private company?

BioCytex is a private company. It is classified as corporate owned and is currently operating.

When was BioCytex founded?

BioCytex was founded in 1992. It employs 11 to 50 people.

Where is BioCytex based?

BioCytex is headquartered in Marseille, France, in the Europe region.

How does BioCytex make money?

Two revenue lines are on record. Diagnostic products and kits are the primary driver. The others are custom development services.

Who are BioCytex's main competitors?

NanoFCM is listed as an emerging player. Direct peers are Beckman Coulter, Bio-Rad Laboratories, Miltenyi Biotec, BD Biosciences, Cell Signaling Technology and Abcam. Broad incumbents are Sysmex, Diagnostica Stago and Thermo Fisher Scientific.

Does BioCytex have an API?

No public API is recorded for BioCytex.

What industry is BioCytex in?

BioCytex's product category is Hemostasis Diagnostics Reagents. Its primary akta.pro industry code is HLAHAAAF, Flow Cytometry & Cellular Analysis Diagnostics, with a secondary code of HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales